Clinical Trial Update: Efficacy and Safety of LAS41003 in the Treatment of Intertriginous Candida Infections [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating LAS41003 for candidiasis (including intertriginous Candida infections) has completed, with efficacy and safety assessments reported.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Candidiasis

Drugs mentioned

• LAS41003

Snippet

Sponsor: Almirall, S.A. | Conditions: Candidiasis | Phase 2 | Status: COMPLETED